Transforming Growth Factor-beta Type I Receptor Inhibitor Induces Functional and Morphologic Recovery in a Rat Model of Erectile Dysfunction and Cavernous Fibrosis.
- Author:
Ji Kan RYU
1
;
Seung Min OH
;
Hai Rong JIN
;
Kang Moon SONG
;
Mi Hye KWON
;
Do Kyung KIM
;
Jun Kyu SUH
Author Information
- Publication Type:Original Article
- Keywords: Erectile dysfunction; Fibrosis; Transforming growth factor beta; TGF-beta type I receptor
- MeSH: Activin Receptors; Adenoviridae; Animals; Arterial Pressure; Caves; Collagen; Electric Stimulation; Erectile Dysfunction; Fibrosis; Hydroxyproline; Male; Muscle, Smooth; Penis; Protein-Serine-Threonine Kinases; Rats; Rats, Sprague-Dawley; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1
- From:Korean Journal of Andrology 2012;30(1):23-30
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To examine the effectiveness of small-molecule inhibitor of transforming growth factor-beta (TGF-beta) type I receptor, an activin receptor-like kinase 5 (ALK5), on erectile dysfunction (ED) in a rat model of cavernous fibrosis, in which fibrosis was induced by intracavernous injection of adenovirus expressing TGF-beta1 (Ad-TGF-beta1). MATERIALS AND METHODS: Four-month-old Sprague-Dawley rats were divided into four groups (n=10 per group): age-matched controls without treatment, age-matched controls receiving intracavernous injection of LacZ adenovirus, and cavernous fibrosis rats receiving an intracavernous injection of saline or ALK5 inhibitor (5 mg/kg). ALK5 inhibitor or saline was administered on day 5 after injection of Ad-TGF-beta1. On day 30, erectile function was assessed by electrical stimulation of the cavernous nerve and the penis was then harvested for histologic studies (n=6 per group) and for the measurement of the hydroxyproline level (n=4 per group). RESULTS: Ad-TGF-beta1-induced cavernous fibrosis rats treated with saline showed a significant decrease in cavernous smooth muscle and endothelial content, and an increase in collagen deposition, which resulted in profound deterioration of all erectile function parameters, such as the ratios of maximal intracavernous pressure (ICP), total ICP, and slope to mean arterial pressure. ALK5 inhibitor significantly restored erectile function in a rat model of cavernous fibrosis by increasing cavernous smooth muscle and endothelial content, and by blocking cavernous fibrosis. CONCLUSIONS: The results suggest that inhibition of the TGF-beta pathway is a promising therapeutic strategy for the treatment of ED related to cavernous fibrosis from various causes.
